<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:IMNN="http://imunon.com/20251231"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="imnn-20251231.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_Dr.LindborgMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">IMNN:Dr.LindborgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_Dr.LindborgMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">IMNN:Dr.LindborgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TardugnoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">IMNN:TardugnoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_Dr.LeGoffMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">IMNN:Dr.LeGoffMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_Dr.LeGoffMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">IMNN:Dr.LeGoffMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="From2024-06-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_ecd_NonPeoNeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_Dr.LindborgMember_custom_DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">IMNN:DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">IMNN:Dr.LindborgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_ecd_NonPeoNeoMember_custom_DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">IMNN:DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TardugnoMember_custom_DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">IMNN:DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">IMNN:TardugnoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_Dr.LeGoffMember_custom_DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">IMNN:DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">IMNN:Dr.LeGoffMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_Dr.LindborgMember_custom_DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">IMNN:DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">IMNN:Dr.LindborgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">IMNN:DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_Dr.LeGoffMember_custom_DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">IMNN:DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">IMNN:Dr.LeGoffMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">IMNN:DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_Dr.LindborgMember_custom_IncreaseForTheinclusionOfRule402VEquityValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">IMNN:IncreaseForTheinclusionOfRule402VEquityValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">IMNN:Dr.LindborgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_ecd_NonPeoNeoMember_custom_IncreaseForTheinclusionOfRule402VEquityValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">IMNN:IncreaseForTheinclusionOfRule402VEquityValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TardugnoMember_custom_IncreaseForTheinclusionOfRule402VEquityValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">IMNN:IncreaseForTheinclusionOfRule402VEquityValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">IMNN:TardugnoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_Dr.LeGoffMember_custom_IncreaseForTheinclusionOfRule402VEquityValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">IMNN:IncreaseForTheinclusionOfRule402VEquityValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">IMNN:Dr.LeGoffMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_Dr.LindborgMember_custom_IncreaseForTheinclusionOfRule402VEquityValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">IMNN:IncreaseForTheinclusionOfRule402VEquityValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">IMNN:Dr.LindborgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_IncreaseForTheinclusionOfRule402VEquityValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">IMNN:IncreaseForTheinclusionOfRule402VEquityValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_Dr.LeGoffMember_custom_IncreaseForTheinclusionOfRule402VEquityValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">IMNN:IncreaseForTheinclusionOfRule402VEquityValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">IMNN:Dr.LeGoffMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_IncreaseForTheinclusionOfRule402VEquityValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">IMNN:IncreaseForTheinclusionOfRule402VEquityValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-12-31" id="Fact000004">0000749647</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0011">DEF 14A</dei:DocumentType>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_Dr.LeGoffMember_custom_DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember"
      id="xdx2ixbrl0066"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-12-31" id="Fact000012">IMUNON, INC.</dei:EntityRegistrantName>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000013">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:PvpTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000015">&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eecd--PvpTableTextBlock_zqt3OFTAKb8j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;PEO Summary&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Compensation Table (SCT)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;PEO
    Compensation Actually Paid&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Other
    NEO Average SCT and Actually Paid&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Value
    of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Year (1)(2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;PEO
    SCT Total for Dr. Lindborg&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;PEO
    SCT Total for Mr. Tardugno&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;PEO
    SCT Total for Dr. Le Goff&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Actual
    PEO Compensation paid to Dr. Lindborg (3)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Actual
    PEO Compensation paid to PEO Mr. Tardugno (3)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Actual
    PEO Compensation paid to PEO Dr. Le Goff (3)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;SCT
    Total for Other NEOs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Average
    Actual Compensation Paid Other NEOs (3)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Initial
    Fixed $100 Investment Based on TSR (4)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Net
    Loss (5)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;span&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eecd--PeoTotalCompAmt_c20250101__20251231__ecd--IndividualAxis__custom--Dr.LindborgMember_fKDEpKDIpKGEp_zXNxn1BDayJk" style="border-bottom: Black 1pt solid; width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,029,349&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eecd--PeoActuallyPaidCompAmt_c20250101__20251231__ecd--IndividualAxis__custom--Dr.LindborgMember_fKDEpKDIpKDMpKGEp_zxEv7a7dHey3" style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;751,376&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eecd--NonPeoNeoAvgTotalCompAmt_c20250101__20251231_fKDEpKDIpKGEp_ztEDWDC8cOq7" style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;597,855&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20250101__20251231_fKDEpKDIpKDMpKGEp_zWfKgRrB8cC2" style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;526,176&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eecd--TotalShareholderRtnAmt_pp2d_c20250101__20251231_fKDEpKDIpKDQpKGEp_zCJzcbleql6d" style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17.79&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--NetIncomeLoss_c20250101__20251231_fKDEpKDIpKDUpKGEp_zdbj1epjkAYg" style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,495,028&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;span&gt;(b)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eecd--PeoTotalCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--Dr.LindborgMember_fKDEpKDIpKGIp_zLvIvxxxOcpf" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,189,339&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eecd--PeoTotalCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--TardugnoMember_fKDEpKDIpKGIp_z0C61cDW5Ek3" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;734,810&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eecd--PeoTotalCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--Dr.LeGoffMember_fKDEpKDIpKGIp_zcj9NcjHfNri" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;148,869&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eecd--PeoActuallyPaidCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--Dr.LindborgMember_fKDEpKDIpKDMpKGIp_z22MHoN3y225" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,129,602&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eecd--PeoActuallyPaidCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--TardugnoMember_fKDEpKDIpKDMpKGIp_zOSIBzStS8Ql" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;690,584&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eecd--PeoActuallyPaidCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--Dr.LeGoffMember_fKDEpKDIpKDMpKGIp_zkiMLdZiIr06" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6,685&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_fKDEpKDIpKGIp_z6h7sfzjUIEc" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;567,201&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_fKDEpKDIpKDMpKGIp_zK3TRvTunTIl" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;684,636&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eecd--TotalShareholderRtnAmt_pp2d_c20240101__20241231_fKDEpKDIpKDQpKGIp_zKbpVWrqSEUe" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--NetIncomeLoss_c20240101__20241231_fKDEpKDIpKDUpKGIp_zmpV7YtwRtb5" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18,620,242&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;span&gt;(c)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eecd--PeoTotalCompAmt_c20230101__20231231__ecd--IndividualAxis__custom--Dr.LeGoffMember_fKDEpKDIpKGMp_zpd8grGhMaib" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,055,814&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eecd--PeoActuallyPaidCompAmt_c20230101__20231231__ecd--IndividualAxis__custom--Dr.LeGoffMember_fKDEpKDIpKDMpKGMp_zWb00T7fRbZ7" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;910,533&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_fKDEpKDIpKGMp_zRvUrIKrzpse" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;680,040&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_fKDEpKDIpKDMpKGMp_zmbnOYGHUqL1" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;612,061&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eecd--TotalShareholderRtnAmt_pp2d_c20230101__20231231_fKDEpKDIpKDQpKGMp_zHo2Dq8VLDVb" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NetIncomeLoss_c20230101__20231231_fKDEpKDIpKDUpKGMp_zh3KDydDwpf8" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(19,514,977&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ecd:PvpTableTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="From2025-01-012025-12-31_custom_Dr.LindborgMember"
      decimals="0"
      id="Fact000016"
      unitRef="USD">1029349</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2025-01-012025-12-31_custom_Dr.LindborgMember"
      decimals="0"
      id="Fact000017"
      unitRef="USD">751376</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000018"
      unitRef="USD">597855</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000019"
      unitRef="USD">526176</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2025-01-01to2025-12-31"
      decimals="2"
      id="Fact000020"
      unitRef="USD">17.79</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000021"
      unitRef="USD">14495028</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt
      contextRef="From2024-01-012024-12-31_custom_Dr.LindborgMember"
      decimals="0"
      id="Fact000022"
      unitRef="USD">1189339</ecd:PeoTotalCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2024-01-012024-12-31_custom_TardugnoMember"
      decimals="0"
      id="Fact000023"
      unitRef="USD">734810</ecd:PeoTotalCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2024-01-012024-12-31_custom_Dr.LeGoffMember"
      decimals="0"
      id="Fact000024"
      unitRef="USD">148869</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2024-01-012024-12-31_custom_Dr.LindborgMember"
      decimals="0"
      id="Fact000025"
      unitRef="USD">1129602</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2024-01-012024-12-31_custom_TardugnoMember"
      decimals="0"
      id="Fact000026"
      unitRef="USD">690584</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2024-01-012024-12-31_custom_Dr.LeGoffMember"
      decimals="0"
      id="Fact000027"
      unitRef="USD">-6685</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000028"
      unitRef="USD">567201</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000029"
      unitRef="USD">684636</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2024-01-012024-12-31"
      decimals="2"
      id="Fact000030"
      unitRef="USD">63.33</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000031"
      unitRef="USD">-18620242</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt
      contextRef="From2023-01-012023-12-31_custom_Dr.LeGoffMember"
      decimals="0"
      id="Fact000032"
      unitRef="USD">1055814</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2023-01-012023-12-31_custom_Dr.LeGoffMember"
      decimals="0"
      id="Fact000033"
      unitRef="USD">910533</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000034"
      unitRef="USD">680040</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000035"
      unitRef="USD">612061</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2023-01-012023-12-31"
      decimals="2"
      id="Fact000036"
      unitRef="USD">45.33</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000037"
      unitRef="USD">-19514977</us-gaap:NetIncomeLoss>
    <ecd:NamedExecutiveOfficersFnTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000047">&lt;p id="xdx_897_eecd--NamedExecutiveOfficersFnTextBlock_dU_zCnypiwxW4db" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    PEOs and Other NEOs for the applicable years were as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025:
    &lt;span id="xdx_90E_eecd--PeoName_c20250101__20251231_zFhSIzuYuscc"&gt;Dr. Lindborg&lt;/span&gt; served as the PEO. Mr. Tardugno and Dr. Faller served as the Other NEO&#x2019;s for 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024:
    &lt;span id="xdx_901_eecd--PeoName_c20240101__20240331_zt5UiXDBlAXe"&gt;Dr. Le Goff&lt;/span&gt; served as the PEO until March 2024, &lt;span id="xdx_905_eecd--PeoName_c20240401__20240531_zrOYse45qZpe"&gt;Mr. Tardugno&lt;/span&gt; served as the PEO until May 2024, and &lt;span id="xdx_900_eecd--PeoName_c20240601__20241231_zFbHV91wSyya"&gt;Dr. Lindborg&lt;/span&gt; joined in May 2024
    as the PEO. Although Mr. Tardugno was an executive officer but not the PEO for the latter part of 2024, since he served as the PEO
    for a portion of the year he is not included as an Other NEO for any portion of 2024. Dr. Anwer, Mr. Gaiero and Mr. Church served
    as the Other NEO&#x2019;s for 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023:
    &lt;span id="xdx_906_eecd--PeoName_c20230101__20231231_zwnsFbNPGQUe"&gt;Dr. Le Goff&lt;/span&gt; served as the PEO, and Dr. Anwer and Mr. Church as the Other NEO&#x2019;s for 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</ecd:NamedExecutiveOfficersFnTextBlock>
    <ecd:PeoName contextRef="From2025-01-01to2025-12-31" id="Fact000048">Dr. Lindborg</ecd:PeoName>
    <ecd:PeoName contextRef="From2024-01-012024-03-31" id="Fact000049">Dr. Le Goff</ecd:PeoName>
    <ecd:PeoName contextRef="From2024-04-012024-05-31" id="Fact000050">Mr. Tardugno</ecd:PeoName>
    <ecd:PeoName contextRef="From2024-06-012024-12-31" id="Fact000051">Dr. Lindborg</ecd:PeoName>
    <ecd:PeoName contextRef="From2023-01-012023-12-31" id="Fact000052">Dr. Le Goff</ecd:PeoName>
    <ecd:AdjToPeoCompFnTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000054">&lt;p id="xdx_895_eecd--AdjToPeoCompFnTextBlock_dU_zML3LtuBT1Ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    2025 Summary Compensation Table totals reported for the PEOs and the average of the Other NEOs for each year were subject to the
    following adjustments per item 402(v)(2)(iii) of Regulations S-K to calculate &#x201c;compensation actually paid&#x201d;:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;PEO&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Average
    for other NEOs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;PEO
    (Mr. Tardugno) &#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;PEO
    (Dr. Le Goff)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;PEO
    (Dr. Lindborg)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Average
    for Other NEOs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;PEO&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Average
    for Other NEOs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Summary Compensation Table Total&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eecd--PeoTotalCompAmt_c20250101__20251231__ecd--IndividualAxis__custom--Dr.LindborgMember_zLuyb7SRsdJ5" style="width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,029,349&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eecd--NonPeoNeoAvgTotalCompAmt_c20250101__20251231__ecd--IndividualAxis__ecd--NonPeoNeoMember_zN49Uv1yHhmh" style="width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;597,855&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eecd--PeoTotalCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--TardugnoMember_zGdL64MtWe7f" style="width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;734,810&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eecd--PeoTotalCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--Dr.LeGoffMember_zbe2aPIba8fk" style="width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;148,869&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eecd--PeoTotalCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--Dr.LindborgMember_zIt90UqcW7k" style="width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,189,339&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--NonPeoNeoMember_zv6w6VIoQcci" style="width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;567,201&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eecd--PeoTotalCompAmt_c20230101__20231231__ecd--IndividualAxis__custom--Dr.LeGoffMember_zl61LYaUGUzc" style="width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,055,814&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--NonPeoNeoMember_zKliweJQcH2e" style="width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;680,040&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;ADJUSTMENTS &lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deductions for amounts reported under the &#x201c;Stock
    Awards&#x201d; and &#x201c;Option Awards&#x201d; columns of the Summary Compensation Table(a)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eecd--AdjToCompAmt_c20250101__20251231__ecd--IndividualAxis__custom--Dr.LindborgMember__ecd--AdjToCompAxis__custom--DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember_fYSk___zqvgpk7NH6K9" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(104,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eecd--AdjToCompAmt_c20250101__20251231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember_fYSk___zfT00taar862" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(55,773&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--TardugnoMember__ecd--AdjToCompAxis__custom--DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember_fYSk___zPNTEzn4tPM2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(213,072&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--Dr.LeGoffMember__ecd--AdjToCompAxis__custom--DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember_fYSk___z9tz6sqNbhY9" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0066"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--Dr.LindborgMember__ecd--AdjToCompAxis__custom--DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember_fYSk___zoFvknxXIChc" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(362,141&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember_fYSk___z8u23CVHP5L9" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;90,950&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__custom--Dr.LeGoffMember__ecd--AdjToCompAxis__custom--DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember_fYSk___zKxot9jvLvgl" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(107,775&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember_fYSk___zysKiwdI2Fe8" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(83,100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Increase for the inclusion
    of Rule 402(v) Equity Value (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eecd--AdjToCompAmt_c20250101__20251231__ecd--IndividualAxis__custom--Dr.LindborgMember__ecd--AdjToCompAxis__custom--IncreaseForTheinclusionOfRule402VEquityValueMember_fYSk___zLuSaMtdz3tk" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(173,973&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eecd--AdjToCompAmt_c20250101__20251231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--IncreaseForTheinclusionOfRule402VEquityValueMember_fYSk___zStEx3bRZOo1" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,906&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--TardugnoMember__ecd--AdjToCompAxis__custom--IncreaseForTheinclusionOfRule402VEquityValueMember_fYSk___zY1Rd4VMOKH5" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;168,846&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--Dr.LeGoffMember__ecd--AdjToCompAxis__custom--IncreaseForTheinclusionOfRule402VEquityValueMember_fYSk___z0sgqRjG8XY1" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(155,554&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--Dr.LindborgMember__ecd--AdjToCompAxis__custom--IncreaseForTheinclusionOfRule402VEquityValueMember_fYSk___zeYhl81d3tsk" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;302,404&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eecd--AdjToCompAmt_c20240101__20241231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--IncreaseForTheinclusionOfRule402VEquityValueMember_fYSk___z1Wzw2HKnvQ1" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;26,486&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__custom--Dr.LeGoffMember__ecd--AdjToCompAxis__custom--IncreaseForTheinclusionOfRule402VEquityValueMember_fYSk___zCxCE3q9mRq6" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(37,506&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eecd--AdjToCompAmt_c20230101__20231231__ecd--IndividualAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__custom--IncreaseForTheinclusionOfRule402VEquityValueMember_fYSk___zhnG6nhxgno9" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,120&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Compensation Actually
    Paid&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eecd--PeoActuallyPaidCompAmt_c20250101__20251231__ecd--IndividualAxis__custom--Dr.LindborgMember_ztc7kDV8y0td" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;751,376&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20250101__20251231__ecd--IndividualAxis__ecd--NonPeoNeoMember_zl3oZdV2kKP3" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;526,176&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eecd--PeoActuallyPaidCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--TardugnoMember_zE92VJR0r1gk" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;690,584&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eecd--PeoActuallyPaidCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--Dr.LeGoffMember_zY2AoeiR1gz3" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6,685&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eecd--PeoActuallyPaidCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--Dr.LindborgMember_zn5AUN70jMn5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,129,602&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231__ecd--IndividualAxis__ecd--NonPeoNeoMember_zpQA0PYdkSkh" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;684,636&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eecd--PeoActuallyPaidCompAmt_c20230101__20231231__ecd--IndividualAxis__custom--Dr.LeGoffMember_zevE7lZdTdFh" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;910,533&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231__ecd--IndividualAxis__ecd--NonPeoNeoMember_zCrbzmPExLdk" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;612,061&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F06_zq3ZpGuR08j1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F10_zc3cU77it5c6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation
    Actually Paid excludes the Stock Awards and Option Awards columns from the relevant fiscal year&#x2019;s Summary Compensation Table
    total. &lt;span id="xdx_901_eecd--Additional402vDisclosureTextBlock_c20250101__20251231_zG9SvSYV08Dk"&gt;The Rule 402(v) Equity Values instead reflect the aggregate of the following components, as applicable: (i) the fair value
    as of the end of the listed fiscal year of unvested equity awards granted in that year; (ii) the change in fair value during the
    listed fiscal year of equity awards granted in prior years that remained outstanding and unvested at the end of the listed fiscal
    year; and (iii) the change in fair value during the listed fiscal year through the vesting date of equity awards granted in prior
    years that vested during the listed fiscal year, less the fair value at the end of the prior year of awards granted prior to the
    listed fiscal year that failed to meet applicable vesting conditions during the listed fiscal year.&lt;/span&gt; Equity values are calculated
    in accordance with FASB ASC Topic 718, and the valuation assumptions used to calculate fair values did not materially differ from
    those disclosed at the time of the grant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</ecd:AdjToPeoCompFnTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="From2025-01-012025-12-31_custom_Dr.LindborgMember"
      decimals="0"
      id="Fact000055"
      unitRef="USD">1029349</ecd:PeoTotalCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2025-01-012025-12-31_ecd_NonPeoNeoMember"
      decimals="0"
      id="Fact000056"
      unitRef="USD">597855</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2024-01-012024-12-31_custom_TardugnoMember"
      decimals="0"
      id="Fact000057"
      unitRef="USD">734810</ecd:PeoTotalCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2024-01-012024-12-31_custom_Dr.LeGoffMember"
      decimals="0"
      id="Fact000058"
      unitRef="USD">148869</ecd:PeoTotalCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2024-01-012024-12-31_custom_Dr.LindborgMember"
      decimals="0"
      id="Fact000059"
      unitRef="USD">1189339</ecd:PeoTotalCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember"
      decimals="0"
      id="Fact000060"
      unitRef="USD">567201</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2023-01-012023-12-31_custom_Dr.LeGoffMember"
      decimals="0"
      id="Fact000061"
      unitRef="USD">1055814</ecd:PeoTotalCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember"
      decimals="0"
      id="Fact000062"
      unitRef="USD">680040</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2025-01-012025-12-31_custom_Dr.LindborgMember_custom_DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember"
      decimals="0"
      id="Fact000063"
      unitRef="USD">-104000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2025-01-012025-12-31_ecd_NonPeoNeoMember_custom_DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember"
      decimals="0"
      id="Fact000064"
      unitRef="USD">-55773</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_TardugnoMember_custom_DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember"
      decimals="0"
      id="Fact000065"
      unitRef="USD">-213072</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_Dr.LindborgMember_custom_DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember"
      decimals="0"
      id="Fact000067"
      unitRef="USD">-362141</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember"
      decimals="0"
      id="Fact000068"
      unitRef="USD">90950</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_custom_Dr.LeGoffMember_custom_DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember"
      decimals="0"
      id="Fact000069"
      unitRef="USD">-107775</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_DeductionsForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember"
      decimals="0"
      id="Fact000070"
      unitRef="USD">-83100</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2025-01-012025-12-31_custom_Dr.LindborgMember_custom_IncreaseForTheinclusionOfRule402VEquityValueMember"
      decimals="0"
      id="Fact000071"
      unitRef="USD">-173973</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2025-01-012025-12-31_ecd_NonPeoNeoMember_custom_IncreaseForTheinclusionOfRule402VEquityValueMember"
      decimals="0"
      id="Fact000072"
      unitRef="USD">-15906</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_TardugnoMember_custom_IncreaseForTheinclusionOfRule402VEquityValueMember"
      decimals="0"
      id="Fact000073"
      unitRef="USD">168846</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_Dr.LeGoffMember_custom_IncreaseForTheinclusionOfRule402VEquityValueMember"
      decimals="0"
      id="Fact000074"
      unitRef="USD">-155554</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_Dr.LindborgMember_custom_IncreaseForTheinclusionOfRule402VEquityValueMember"
      decimals="0"
      id="Fact000075"
      unitRef="USD">302404</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_custom_IncreaseForTheinclusionOfRule402VEquityValueMember"
      decimals="0"
      id="Fact000076"
      unitRef="USD">26486</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_custom_Dr.LeGoffMember_custom_IncreaseForTheinclusionOfRule402VEquityValueMember"
      decimals="0"
      id="Fact000077"
      unitRef="USD">-37506</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_custom_IncreaseForTheinclusionOfRule402VEquityValueMember"
      decimals="0"
      id="Fact000078"
      unitRef="USD">15120</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2025-01-012025-12-31_custom_Dr.LindborgMember"
      decimals="0"
      id="Fact000079"
      unitRef="USD">751376</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2025-01-012025-12-31_ecd_NonPeoNeoMember"
      decimals="0"
      id="Fact000080"
      unitRef="USD">526176</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2024-01-012024-12-31_custom_TardugnoMember"
      decimals="0"
      id="Fact000081"
      unitRef="USD">690584</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2024-01-012024-12-31_custom_Dr.LeGoffMember"
      decimals="0"
      id="Fact000082"
      unitRef="USD">-6685</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2024-01-012024-12-31_custom_Dr.LindborgMember"
      decimals="0"
      id="Fact000083"
      unitRef="USD">1129602</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember"
      decimals="0"
      id="Fact000084"
      unitRef="USD">684636</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2023-01-012023-12-31_custom_Dr.LeGoffMember"
      decimals="0"
      id="Fact000085"
      unitRef="USD">910533</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember"
      decimals="0"
      id="Fact000086"
      unitRef="USD">612061</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:Additional402vDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000088">The Rule 402(v) Equity Values instead reflect the aggregate of the following components, as applicable: (i) the fair value
    as of the end of the listed fiscal year of unvested equity awards granted in that year; (ii) the change in fair value during the
    listed fiscal year of equity awards granted in prior years that remained outstanding and unvested at the end of the listed fiscal
    year; and (iii) the change in fair value during the listed fiscal year through the vesting date of equity awards granted in prior
    years that vested during the listed fiscal year, less the fair value at the end of the prior year of awards granted prior to the
    listed fiscal year that failed to meet applicable vesting conditions during the listed fiscal year.</ecd:Additional402vDisclosureTextBlock>
    <ecd:TabularListTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000090">&lt;p id="xdx_899_eecd--TabularListTableTextBlock_dU_zfREVN702k2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financial
Performance Measures&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
do not currently use financial performance measures to link executive compensation actually paid to our NEOs to our performance. However,
as discussed above under &#x201c;Executive Compensation,&#x201d; we do utilize non-financial measures such as clinical development progress
and timelines, manufacturing measures and progress towards commercialization.&lt;/span&gt;&lt;/p&gt;

</ecd:TabularListTableTextBlock>
    <ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000092">&lt;p id="xdx_891_eecd--CompActuallyPaidVsTotalShareholderRtnTextBlock_dU_zZvbn3lyW4tg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Table
Compensation Actually Paid and Cumulative TSR&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
amount of compensation actually paid to Dr. Lindborg in 2025, Dr. Lindborg, Mr. Tardugno and Dr. Le Goff in 2024, and Dr. Le Goff in
2023, is aligned with our TSR over the three years presented in the table, reflecting the impact of the hiring of Dr. Lindborg as President
and Chief Executive Officer in 2024 and the termination of Dr. Le Goff in 2024 and cash payments made in connection therewith. Notwithstanding
those payments, a substantial amount of Dr. Lindborg&#x2019;s compensation was in the form of stock option awards that vest in four equal
installments, with one-fourth of the grant vesting each on the first, second, third and fourth anniversary of the date of grant. A substantial
amount of Mr. Tardugno&#x2019;s compensation was in the form of stock option awards that vest one-half immediately and one-fourth on each
of the first and second anniversaries of the date of grant. A substantial amount of Dr. Le Goff&#x2019;s compensation was in the form
of stock option awards that vested in three equal installments, with one-third of the grant vesting each on the first, second and third
anniversary of the date of grant. As the trading price of our common stock fluctuates, so does the value of the stock options and, accordingly,
the amount of compensation actually paid to the PEO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
amount of compensation actually paid to the Other NEOs is aligned with our TSR over the three years presented in the table. A significant
portion of the compensation actually paid to the Other NEOs is composed of stock option awards which vest either (i) in three installments,
commencing one-third immediately and one-third on each of the first and second anniversary of the date of grant or (iii) one-half immediately
and one-fourth on each of the first and second anniversary of the date of grant.&lt;/span&gt;&lt;/p&gt;

</ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock>
    <ecd:CompActuallyPaidVsNetIncomeTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000094">&lt;p id="xdx_891_eecd--CompActuallyPaidVsNetIncomeTextBlock_dU_zSVhOIwQClJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Compensation
Actually Paid and Net Income&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
amount of compensation actually paid to Dr. Lindborg in 2025, Dr. Lindborg, Mr. Tardugno and Dr. Le Goff in 2024, and Dr. Le Goff in
2023, and to the Other NEOs is not aligned with our net income over the three years presented in the table. As a clinical stage biotechnology
company, we have incurred substantial operating losses, principally from expenses associated with the Company&#x2019;s research and development
programs, clinical trials conducted in connection with the Company&#x2019;s drug candidates, and applications and submissions to the U.S.
Food and Drug Administration. We have substantial future capital requirements to continue our research and development activities and
advance our drug candidates through various development stages. Accordingly, net income is not a performance measure we use in determining
executive compensation. As discussed above, under &#x201c;Compensation Discussion and Analysis,&#x201d; we use a number of corporate goals
that may include research and development, regulatory, manufacturing, organization and financial goals which we believe are important
to building stockholder value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2025, our net loss was $14.5 million compared to a net loss of $18.6 million for the year ended December
31, 2024.&lt;/span&gt;&lt;/p&gt;

</ecd:CompActuallyPaidVsNetIncomeTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000016"
          xlink:label="Fact000016"
          xlink:type="locator"/>
        <link:footnote id="Footnote000038" xlink:label="Footnote000038" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">We
    are a smaller reporting company and, accordingly, we have not included any information in this table for 2022 or 2021.</link:footnote>
        <link:footnote id="Footnote000039" xlink:label="Footnote000039" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    PEOs and Other NEOs for the applicable years were as follows:</link:footnote>
        <link:footnote id="Footnote000043" xlink:label="Footnote000043" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">2025:
    Dr. Lindborg served as the PEO. Mr. Tardugno and Dr. Faller served as the Other NEO&#x2019;s for 2025.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000016"
          xlink:to="Footnote000043"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000016"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000016"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000017"
          xlink:label="Fact000017"
          xlink:type="locator"/>
        <link:footnote id="Footnote000040" xlink:label="Footnote000040" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    2025 Summary Compensation Table totals reported for the PEOs and the average of the Other NEOs for each year were subject to the
    following adjustments per item 402(v)(2)(iii) of Regulations S-K to calculate &#x201c;compensation actually paid&#x201d;:</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000017"
          xlink:to="Footnote000043"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000017"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000017"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000017"
          xlink:to="Footnote000040"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000018"
          xlink:label="Fact000018"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000018"
          xlink:to="Footnote000043"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000018"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000018"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000019"
          xlink:label="Fact000019"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000019"
          xlink:to="Footnote000043"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000019"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000019"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000019"
          xlink:to="Footnote000040"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000020"
          xlink:label="Fact000020"
          xlink:type="locator"/>
        <link:footnote id="Footnote000041" xlink:label="Footnote000041" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Measured
    as the value of a $100 investment in Imunon, Inc. common stock at market close on December 31, 2022, the last trading day in 2022,
    through and including the end of the indicated year.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000020"
          xlink:to="Footnote000043"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000020"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000020"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000020"
          xlink:to="Footnote000041"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000021"
          xlink:label="Fact000021"
          xlink:type="locator"/>
        <link:footnote id="Footnote000042" xlink:label="Footnote000042" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Calculated
    in accordance with U.S. GAAP.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000021"
          xlink:to="Footnote000042"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000021"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000021"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000021"
          xlink:to="Footnote000043"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000022"
          xlink:label="Fact000022"
          xlink:type="locator"/>
        <link:footnote id="Footnote000044" xlink:label="Footnote000044" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">2024:
    Dr. Le Goff served as the PEO until March 2024, Mr. Tardugno served as the PEO until May 2024, and Dr. Lindborg joined in May 2024
    as the PEO. Although Mr. Tardugno was an executive officer but not the PEO for the latter part of 2024, since he served as the PEO
    for a portion of the year he is not included as an Other NEO for any portion of 2024. Dr. Anwer, Mr. Gaiero and Mr. Church served
    as the Other NEO&#x2019;s for 2024.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000022"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000022"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000022"
          xlink:to="Footnote000044"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000023"
          xlink:label="Fact000023"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000023"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000023"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000023"
          xlink:to="Footnote000044"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000024"
          xlink:label="Fact000024"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000024"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000024"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000024"
          xlink:to="Footnote000044"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000025"
          xlink:label="Fact000025"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000025"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000025"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000025"
          xlink:to="Footnote000044"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000025"
          xlink:to="Footnote000040"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000026"
          xlink:label="Fact000026"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000026"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000026"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000026"
          xlink:to="Footnote000044"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000026"
          xlink:to="Footnote000040"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000027"
          xlink:label="Fact000027"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000027"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000027"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000027"
          xlink:to="Footnote000044"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000027"
          xlink:to="Footnote000040"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000028"
          xlink:label="Fact000028"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000028"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000028"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000028"
          xlink:to="Footnote000044"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000029"
          xlink:label="Fact000029"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000029"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000029"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000029"
          xlink:to="Footnote000044"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000029"
          xlink:to="Footnote000040"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000030"
          xlink:label="Fact000030"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000030"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000030"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000030"
          xlink:to="Footnote000041"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000030"
          xlink:to="Footnote000044"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000031"
          xlink:label="Fact000031"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000031"
          xlink:to="Footnote000042"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000031"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000031"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000031"
          xlink:to="Footnote000044"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000032"
          xlink:label="Fact000032"
          xlink:type="locator"/>
        <link:footnote id="Footnote000045" xlink:label="Footnote000045" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">2023:
    Dr. Le Goff served as the PEO, and Dr. Anwer and Mr. Church as the Other NEO&#x2019;s for 2023.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000032"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000032"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000032"
          xlink:to="Footnote000045"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000033"
          xlink:label="Fact000033"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000033"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000033"
          xlink:to="Footnote000045"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000033"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000033"
          xlink:to="Footnote000040"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000034"
          xlink:label="Fact000034"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000034"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000034"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000034"
          xlink:to="Footnote000045"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000035"
          xlink:label="Fact000035"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000035"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000035"
          xlink:to="Footnote000045"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000035"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000035"
          xlink:to="Footnote000040"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000036"
          xlink:label="Fact000036"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000036"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000036"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000036"
          xlink:to="Footnote000041"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000036"
          xlink:to="Footnote000045"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000037"
          xlink:label="Fact000037"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000037"
          xlink:to="Footnote000042"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000037"
          xlink:to="Footnote000039"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000037"
          xlink:to="Footnote000038"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000037"
          xlink:to="Footnote000045"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000063"
          xlink:label="Fact000063"
          xlink:type="locator"/>
        <link:footnote id="Footnote000087" xlink:label="Footnote000087" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Compensation
    Actually Paid excludes the Stock Awards and Option Awards columns from the relevant fiscal year&#x2019;s Summary Compensation Table
    total. <xhtml:span id="xdx_901_eecd--Additional402vDisclosureTextBlock_c20250101__20251231_zG9SvSYV08Dk">The Rule 402(v) Equity Values instead reflect the aggregate of the following components, as applicable: (i) the fair value
    as of the end of the listed fiscal year of unvested equity awards granted in that year; (ii) the change in fair value during the
    listed fiscal year of equity awards granted in prior years that remained outstanding and unvested at the end of the listed fiscal
    year; and (iii) the change in fair value during the listed fiscal year through the vesting date of equity awards granted in prior
    years that vested during the listed fiscal year, less the fair value at the end of the prior year of awards granted prior to the
    listed fiscal year that failed to meet applicable vesting conditions during the listed fiscal year.</xhtml:span> Equity values are calculated
    in accordance with FASB ASC Topic 718, and the valuation assumptions used to calculate fair values did not materially differ from
    those disclosed at the time of the grant.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000063"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000064"
          xlink:label="Fact000064"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000064"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000065"
          xlink:label="Fact000065"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000065"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0066"
          xlink:label="xdx2ixbrl0066"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0066"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000067"
          xlink:label="Fact000067"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000067"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000068"
          xlink:label="Fact000068"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000068"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000069"
          xlink:label="Fact000069"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000069"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000070"
          xlink:label="Fact000070"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000070"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000071"
          xlink:label="Fact000071"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000071"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000072"
          xlink:label="Fact000072"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000072"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000073"
          xlink:label="Fact000073"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000073"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000074"
          xlink:label="Fact000074"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000074"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000075"
          xlink:label="Fact000075"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000075"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000076"
          xlink:label="Fact000076"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000076"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000077"
          xlink:label="Fact000077"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000077"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000078"
          xlink:label="Fact000078"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000078"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
